SynthesisBMC cancer2015
Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.
Synthesis in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Liquid biopsy in breast cancer: Redefining precision medicine.The journal of liquid biopsy · 2025Review
- Article
- Promoter hypermethylation of RARB and GSTP1 genes in plasma cell-free DNA as breast cancer biomarkers in Peruvian women.Molecular genetics & genomic medicine · 2023Article
- Genetic association between rs1695 in glutathione S-transferase P1 and risk of periodontitis: a pilot study.Molecular biology research communications · 2023Article
- Methylation profiles of global LINE-1 DNA and the GSTP1 promoter region in children exposed to lead (Pb).Epigenetics · 2022Article
- Epigenetic Determinants of Racial Disparity in Breast Cancer: Looking beyond Genetic Alterations.Cancers · 2022Review
- Genome-wide aberrant methylation in primary metastatic UM and their matched metastases.Scientific reports · 2022Article
- Estimating DNA methylation potential energy landscapes from nanopore sequencing data.Scientific reports · 2021Article
- Methylation of Glutathione-S-Transferase P1 Promotor in Egyptian Females with Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Transcriptional Activation ofFrontiers in oncology · 2019Article
- Evaluation of glutathione S-transferase pi 1 expression and gene promoter methylation in Moroccan patients with urothelial bladder cancer.Molecular genetics & genomic medicine · 2018Article
- Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast CancerAsian Pacific journal of cancer prevention : APJCP · 2018Article
- DNA methylation profiles in cancer diagnosis and therapeutics.Clinical and experimental medicine · 2018Review
- Article
- Article
- Article
- Methylation of kruppel-like factor 2 (KLF2) associates with its expression and non-small cell lung cancer progression.American journal of translational research · 2017Article
- GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.Disease markers · 2016Article
- DNA methylation biomarkers as an early diagnostic tool in the progression of oral squamous cell carcinoma.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlutathione S-transferase P1 (GSTP1) has been reported to function as a tumor suppressor gene in various types of human cancers. Aberrant methylation of tumor-related genes at the promoter regions can inactivate genes, which is important in the carcinogenesis of breast cancer. However, the role of GSTP1 promoter methylation in the occurrence of breast cancer and its relationship with tumor stage and histological grade has not been fully elucidated. Thus, we carried out a meta-analysis to yield a more accurate association.
methodsA systematically literature search was made on PubMed, EMBASE and Web of Science databases for eligible studies. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated by RevMan 5.2 software. Subgroup and sensitivity analyses were conducted to explore the source of heterogeneity.
resultsEventually, 17 articles involving 19 case-control studies were included in the present meta-analysis. Overall, the pooled results indicated that aberrant GSTP1 promoter methylation was significantly associated with the risk of breast cancer (OR = 7.85, 95 % CI = 5.12-12.01; Caucasians OR = 7.23, 95 % CI = 3.76-13.90 and Asians OR = 11.71, 95 % CI = 5.69-24.07). Furthermore, our results revealed that GSTP1 promoter methylation was more often observed in late-stage breast cancer patients compared with early-stage ones (OR = 1.84, 95 % CI = 1.32-2.58). However, no significant association was identified between GSTP1 promoter methylation and histological grade (OR = 0.74, 95 % CI = 0.43-1.26).
conclusionsThe results indicated that GSTP1 promoter methylation probably plays an important role in breast carcinogenesis, which could serve as an effective biomarker for the diagnosis and monitor of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.